Working… Menu

Study of Promethazine for Treatment of Diabetic Gastroparesis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02130622
Recruitment Status : Terminated (Lack of recruitment)
First Posted : May 5, 2014
Results First Posted : May 17, 2018
Last Update Posted : August 7, 2018
American College of Gastroenterology
Information provided by (Responsible Party):
Dartmouth-Hitchcock Medical Center

Brief Summary:
Adult diabetic patients (ages 18-65) with gastric emptying scintigraphy-confirmed delayed gastric emptying will be recruited to participate in the study. Using double-blinded methodology, study participants will be randomly assigned to one of two treatment arms: promethazine 12.5 mg three times daily for 28 days or placebo three times daily for 28 days. The primary outcome will be the change in gastroparesis symptom severity, as measured by the Gastroparesis Cardinal Symptom Index (GCSI) at four weeks compared to baseline. Participants will be seen for a clinic evaluation at weeks 0, 2 and 4, during which symptom scores, adverse events and treatment compliance will be assessed. It is hypothesized promethazine treatment will be superior to placebo in improving symptoms of gastroparesis.

Condition or disease Intervention/treatment Phase
Diabetic Gastroparesis Drug: Promethazine Drug: Sugar pill Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 3 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Pilot, Randomized, Double-blind, Placebo-controlled Trial of Promethazine for Treatment of Diabetic Gastroparesis.
Actual Study Start Date : July 2014
Actual Primary Completion Date : May 14, 2015
Actual Study Completion Date : May 14, 2015

Arm Intervention/treatment
Experimental: Promethazine
Promethazine 12.5 mg P.O. t.i.d. for 4 weeks
Drug: Promethazine
Other Name: Phenergan

Placebo Comparator: Sugar Pill
Placebo P.O. t.i.d. for 4 weeks
Drug: Sugar pill
Other Name: Placebo

Primary Outcome Measures :
  1. Change in Patient-reported Symptoms as Measured by the Gastroparesis Cardinal Symptom Index Score (GCSI, 14) From Week 0 to Week 4. [ Time Frame: 4 weeks ]

Secondary Outcome Measures :
  1. Occurrence of Adverse Events [ Time Frame: 4 weeks ]
  2. Use of Rescue Medication [ Time Frame: 4 weeks ]
    Frequency of use of the "rescue medication" meclizine

  3. The Impact on Work Activity as Measured by the Work Productivity and Activity Impairment Questionnaire. (WPAI). [ Time Frame: 4 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • adult patients 18-65 years of age
  • clinical diagnosis of diabetic gastroparesis.
  • EGD without evidence of gastric outlet obstruction within the past five years
  • gastric emptying scintigraphy test demonstrating >10% solid food retention at 4 hours within the past three years.

Exclusion Criteria:

  • the inability or unwillingness to provide informed consent
  • currently pregnant or breast feeding
  • prior placement of a gastric stimulator
  • pyloric botulinum toxin injection within the past 12 months
  • prior gastric surgery
  • history of a connective tissue disorder
  • use of narcotic medication within the past four weeks
  • hemoglobin A1C >12 mg/dL within the past 3 months
  • current or recent (within past 4 weeks) use of promethazine, metoclopramide or domperidone
  • hypersensitivity or prior adverse reaction to promethazine
  • concomitant use of phenothiazines (i.e. prochlorperazine, chlorpromazine) or other agents likely to increase extrapyramidal reactions
  • concomitant use of tiotropium or ipratropium
  • narrow angle glaucoma
  • urinary retention
  • Parkinson's disease
  • significant psychiatric disease
  • history of seizure.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02130622

Layout table for location information
United States, New Hampshire
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States, 03756
Sponsors and Collaborators
Dartmouth-Hitchcock Medical Center
American College of Gastroenterology
Layout table for investigator information
Principal Investigator: Brian E. Lacy, MD Dartmouth-Hitchcock Medical Center

Layout table for additonal information
Responsible Party: Dartmouth-Hitchcock Medical Center Identifier: NCT02130622    
Other Study ID Numbers: D14076
First Posted: May 5, 2014    Key Record Dates
Results First Posted: May 17, 2018
Last Update Posted: August 7, 2018
Last Verified: July 2018
Keywords provided by Dartmouth-Hitchcock Medical Center:
Diabetic Gastroparesis
Additional relevant MeSH terms:
Layout table for MeSH terms
Stomach Diseases
Gastrointestinal Diseases
Digestive System Diseases
Neurologic Manifestations
Dermatologic Agents
Histamine H1 Antagonists
Histamine Antagonists
Histamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Anti-Allergic Agents
Sleep Aids, Pharmaceutical
Hypnotics and Sedatives
Central Nervous System Depressants
Anesthetics, Local
Sensory System Agents
Peripheral Nervous System Agents
Autonomic Agents
Gastrointestinal Agents